Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 63 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 63 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Neurology Department, Petra-Olympou Psychiatric Hospital, Katerini, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Feldmann H.H., Ferris S., Winblad B., Sfikas N., Mancione L., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 6: 501-512 (2007)

3. Winblad B.,  Gauthier S., Sinto L., Feldman H., et al.: Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology: (2008)

4. Petersen R.C., Thomas R.G., Grundman M., Bennet D., Doody R., Ferris S., et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Eng. J. Med. 352: 2379-2388 (2005)

5. Raschetti R., Albanese E., Vanacore N., Maggini M.: Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomized trials. PLoS Med, 4(11): e338 (2007)

6. Dubey A.K., Shankar P.R., Upadhyaya D., Deshpande V.Y.: Ginkgo biloba: an appraisal. Kathmandu Univ. Med. J. (KUMJ) 2: 225-229 (2004)

7. Birks J., Grimley Evans J.: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2: CD003120 (2007)

8. Malouf R., Areosa Sastre A.: Vitamin B12 for cognition. Cochrane Database Syst. Rev. 3: CD004326 (2003)

9. Malouf M., Grimley E.J., Aroesa S.A.: Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst. Rev. 4: CD004514 (2003)

10. Hajjar I., Schumpert J., Hirth V., et al. The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment.

http://biomed.gerontologyjournals.org/cgi/content/abstract/57/7/M414

11. Doraiswamy M., Steffens D., Mcquoid D.: Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer’s disease: A pilot observational study. http//aja.sagepub.com/cgi/content/short/19/5/275

12. Thai L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuean E., Assaid C., et al.: Rofecoxib Protocol 078 study group. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204-1215 (2005)

13. McNeely W., Goa K.L.: Triflusal. http//www.ncbi.nml.nih,gov/pubmed/9617597

14. Gomez-Isla T., Blesa R., Boada M., Del Ser T., Ferro J.M., Martinez-Lage J.M., et al.: TRIMCI Study Group. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis. Assoc. Disord. 22: 21-29 (2008)

15. Ryan J., Scali J., Carriere I., Ritchie K., Ancelin M.L.: Hormonal treatment, mild cognitive impairment and Alzheimer’s disease. Int. Psychogeriatric. 20: 47-56 (2008)

16. Flicker L., Grimley Evans J.: Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. 2: CD001011 (2000)

17. Mowla A., Mosavinasab M., Haghshenas H., Haghighi A.B.: Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 27: 484-487 (2007)

18. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., et al.: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448 (2008)

19. Jelic V., Kivipeto M., Winbland B.: Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry 77: 429-438 (2006)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr